Clinical and Translational Science

Principles of Human Research

1st Edition - December 15, 2008
Editors: David Robertson, Gordon H. Williams
Language: English
Paperback ISBN:
9 7 8 - 0 - 1 2 - 3 7 3 6 3 9 - 0
eBook ISBN:
9 7 8 - 0 - 0 8 - 0 9 2 0 1 9 - 1

Clinical or translational science is the field of study devoted to investigating human health and disease, interventions and outcomes for the purposes of developing new tr… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Clinical or translational science is the field of study devoted to investigating human health and disease, interventions and outcomes for the purposes of developing new treatment approaches, devices, and modalities to improve health. New molecular tools and diagnostic technologies based on clinical and translational research have lead to a better understanding of human disease and the application of new therapeutics for enhanced health.

Clinical and Translational Science is designed as the most authoritative and modern resource for the broad range of investigators in various medical specialties taking on the challenge of clinical research. Prepared with an international perspective, this resource begins with experimental design and investigative tools to set the scene for readers. It then moves on to human genetics and pharmacology with a focus on statistics, epidemiology, genomic information, drug discovery and development, and clinical trials. Finally, it turns to legal, social, and ethical issues of clinical research concluding with a discussion of future prospects to provide readers with a comprehensive view of the this developing area of science.

List of Contributors

Foreword

Acknowledgments

Introduction to Clinical Research

Part I Fundamental Principles

1 Patient-Oriented Research: Clinical Pathophysiology and Clinical Therapeutics

2 Clinical Trials

Part II Approaches

3 Experimental Design

4 Introduction to Biostatistics Ideas

5 Measurement of Biological Materials

6 Imaging Tools in Human Research

7 Imaging Tools in Cardiovascular Research

8 Nanotechnology in Clinical and Translational Research

9 The Use of Questionnaires and Surveys

10 Information Technology

Part III Infrastructure

11 Clinical and Translational Science Infrastructure

12 Industry-Sponsored Clinical Research in Academia

Part IV Education, Training and Career Choices

13 Training Basic, Clinical and Translational Investigators

14 A Stepwise Approach to a Career in Translational Research

15 Physician Careers in Industry

Part V Funding

16 Governmental Support of Research

17 Support of Health Research by Private Philanthropy

18 Pharmaceutical and Biotechnology Sector Support of Research

Part VI Human Genetics

19 Introduction to Human Genetics

20 Epidemiologic and Population Genetic Studies

21 Pharmacogenetics of Drug Metabolism

Part VII Human Pharmacology

22 Introduction to Clinical Pharmacology

23 Toxicology and Genetics of Adverse Drug Events

24 Good Clinical Practice and Good Laboratory Practice

25 Modern Drug Discovery and Development

Part VIII Societal Context of Human Research

26 Translating Science to the Bedside: The Innovation Pipeline

27 Regulatory Environment

28 Ethical Issues in Translational Research and Clinical Investigation

29 Clinical Research in the Public Eye

Part IX Research in Special Populations

30 Acute Illnesses, Critical Care, Emergency and Surgical Patients

31 Psychiatric Disorders

32 Geriatrics

33 Pediatrics

Part X Population-Based Research

34 Pharmacoeconomics: The Economic Evaluation of New Medical Technology

35 Introduction to Epidemiology

36 Health Services Research: Translating Discovery and Research into Practice and Policy

Part XI Prospectus

37 The Future of Clinical Research

Index

David Robertson

Dr. Robertson graduated from Vanderbilt University in 1969, with a B.A. in Germanic and Slavic Languages. He attended the Arnamagnaen Institute in Copenhagen, Denmark before receiving his medical degree from Vanderbilt University Medical School in 1973. He went on to complete an internship and residency in Medicine at Johns Hopkins Hospital. Robertson was a postdoctoral fellow in Clinical Pharmacology at Vanderbilt for two years before accepting a position as assistant chief of Service in Medicine and instructor in Medicine at Johns Hopkins in 1977.

In 1978, Robertson returned to Vanderbilt as assistant professor of Medicine and Pharmacology, became an associate professor in 1982, then rose to professor in 1986. He spent one year as a visiting professor in the Department of Molecular Endocrinology at National, then served as a visiting professor in the Department of Anatomy and Embryology at University College in London. In 1993, Robertson became director of the Medical Scientist Training Program at Vanderbilt University and also took the position of director of the Division of Movement Disorders in the Department of Neurology, which he held until 2000.

Along with his current roles as professor of Medicine and Pharmacology and professor of Neurology, Robertson is currently the Elton Yates Professor of Autonomic Disorders, director of the General Clinical Research Center and director of the Center for Space Physiology and Medicine for Vanderbilt University.

Robertson currently serves on the Board of Advisors for the World Life Foundation, the NASA Microgravity Human Research Committee, the Merck Advisory Board, and the editorial boards of American Journal of Medicine, Autonomic Neuroscience and Clinical Autnomic Research. He is also associate editor for the Journal of Pharmacology and Experimental Therapeutics.

Affiliations and expertise

Departments of Medicine, Pharmacology, and Neurology, Clinical Research Center, Vanderbilt University, Nashville, TN, USA

Gordon H. Williams

Dr. Williams’ group’s first major goal is the identification of the genetic underpinnings of endocrine factors related to cardiovascular (CV) risk in hypertension and diabetes with the ultimate goal of using genetic markers to develop individualized, personal treatment programs for patients with these diseases. His is a translational research group with interdisciplinary focus in humans and at the bench. The group's major focus in human studies is on careful phenotyping of patients with hypertension and diabetes relative to cardiovascular risk factors. The research focuses on evaluating hormones that can modify vascular contractility and/or salt handling. The major current thrusts are the renin-angiotensin-aldosterone system (RAAS), kallikrein, cortisol, adducin, the beta-2 adrenergic receptor and ion transport systems. The second major goal is to determine the role of aldosterone in producing CV disease at molecular, cellular, organ, whole animal and clinical levels. Recent studies suggest that aldosterone has a wide range of effects including inducing microvascular ischemia, thrombosis, fibrosis, and inflammatory responses many of them potentially mediated by aldosterone’s interaction with caveolins and two recently discovered proteins---striatin and lysine specific demethylase 1 (LSD1). Techniques employed include whole animal physiological studies using normal animals, those made hypertensive and those genetically modified (e.g. knock-outs and transgenics). Molecular and cellular techniques include gene arrays using chip technology, proteomics, confocal microscopy, electrophysiology and in situ hybridization. Finally, the group has just begin the first proof of concept clinical trial for using genetic information to provide personalized medicine.

Affiliations and expertise

Chief, Endocrine Hypertension Division, Brigham and Women's Hospital, Boston, MA, USA